Request Demo
Last update 15 Aug 2026
ISU-104
Last update 15 Aug 2026
Overview
Basic Info
Drug Type Monoclonal antibody |
Synonyms Barecetamab |
Target |
Action antagonists |
Mechanism HER3 antagonists(Receptor tyrosine-protein kinase erbB-3 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 616719785L
Source: *****
Sequence Code 774056829H
Source: *****
Related
1
Clinical Trials associated with ISU-104NCT03552406
A Phase I, Open-label, Dose-finding Study to Assess the Safety, Tolerability and Pharmacokinetics of ISU104, a Human Monoclonal Antibody Targeting ErbB3 in Patients With Advanced Solid Tumors
100 Clinical Results associated with ISU-104
Login to view more data
100 Translational Medicine associated with ISU-104
Login to view more data
100 Patents (Medical) associated with ISU-104
Login to view more data
100 Deals associated with ISU-104
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 1 | South Korea | 27 Apr 2018 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Not Applicable | 15 | Barecetamab and cetuximab combination | boybjoxpdb(kxolqavxnq) = Common adverse drug reactions were diarrhea, stomatitis, dermatitis acneiform and decreased appetite yylqcqcpul (zecomiyeuy ) View more | - | 26 Jun 2023 | ||
NCT03552406 (ESMO2021) Manual  | Phase 1 | 18 | yqkerevxcz(nhntfdmyym) = sxwszlbnng dbdlnuqtaa (ofywzyxydd ) View more | Positive | 16 Sep 2021 | ||
yqkerevxcz(nhntfdmyym) = annszftywq dbdlnuqtaa (ofywzyxydd ) View more | |||||||
Phase 1 | 18 | unfqlbehjy(rppdaptgfy) = 50% in Comb xpnbgpwpmh (qsmguwjrmd ) View more | Positive | 17 Sep 2020 | |||
Phase 1 | 15 | drciyftrtk(whwonpzeqb) = uervgeuucj qqrydrebxv (hxwwjdiswe ) | - | 28 Sep 2019 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free